|Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD||Founder & Executive Chairman||271.45k||N/A||1956|
|Mr. Riccardo Canevari||MD, CEO & Director||1.51M||N/A||N/A|
|Mr. Vittorio Puppo M.D.||Chief Operating Officer||1.03M||N/A||N/A|
|Prof. David Mozley||Chief Medical Officer & Scientific Advisory Board Chair||765.76k||N/A||N/A|
|Dr. Thomas H. Tulip Ph.D.||Chief Business Officer||504.74k||N/A||1953|
|Mr. Phillip Hains||CFO & Company Secretary||N/A||N/A||N/A|
|Dr. Scot L. Harper Ph.D.||Senior Vice President of Clinical Operations||N/A||N/A||1957|
|Mr. Bill Regan||Senior Vice President of Regulatory Strategy||N/A||N/A||N/A|
|Dr. Rama Abu Shmeis||Senior VP of Chemistry, Manufacturing & Controls||N/A||N/A||N/A|
|Mr. Nathan Jong C.A.||Company Secretary||N/A||N/A||N/A|
Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.
Radiopharm Theranostics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.